Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.
Location: Italy, Lombardy, Milan
Employees: 1-10
Total raised: $69.18M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
| 10.07.2026 | XGEN VENTU... | xgenventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.09.2024 | Series B | $51.77M | - |
| 29.04.2020 | Series A | $17.4M | - |
Mentions in press and media 11
| Date | Title | Description |
| 27.09.2024 | Genespire's €46.6 Million Boost: A Leap Towards Pediatric Gene Therapy | In the heart of Milan, a biotechnology company is making waves. Genespire has just secured €46.6 million (approximately $52 million) in a Series B funding round. This is not just another investment; it’s a lifeline for children battling gen... |
| 25.09.2024 | Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic | Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings to date Financing co-led by Sofinnova Partne... |
| 25.09.2024 | Genespire Raises €46.6M in Series B Funding | Genespire, a Milan, Italy-based biotechnology company developing gene therapies for pediatric patients affected by genetic diseases, raised €46.6M in Series B funding. The round was led by Sofinnova Partners, XGEN Venture and CDP Venture Ca... |
| 12.09.2024 | Genespire appoints Karen Aiach-Pignet as Chief Executive Officer | PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12 September 2024 – Genespire, a biotechnology com... |
| 25.01.2024 | Which Italian Life Science Startups Are Pioneering Healthcare Innovations Today? | The Italian life sciences sector is ripe with innovative start-ups that are making waves both locally and internationally. While the fields in this sector are diverse, including everything from biotechnology to health care and artificial in... |
| 07.07.2022 | Genespire appoints Dr. Sabah Sallah as Chief Medical Officer | Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a... |
| 13.07.2021 | Genespire appoints Philippe Mauberna as Chief Financial Officer | Genespire appoints Philippe Mauberna as Chief Financial Officer Former Nanobiotix Chief Financial Officer brings extensive experience in international life sciences finance, successful fundraisings and operations Italy, Milan, 13 July 2021:... |
| 10.08.2020 | These aspiring Milan tech startups secured highest VC fundings in Q2 2020 | The tech startup ecosystem in Milan is vibrant with countless events that attract venture capital funds, business angels, and investor club deals. In addition to the committed and aspiring entrepreneurs and talent out there, Milan is also a... |
| 30.04.2020 | Daily funding roundup - April 30th, 2020 | Resistant AI landed $2.75M; Guilded raised $7M; WindESCo secured $10M; Vida Health picks up $25M Resistant AI: Resistant AI is a security startup whose machine learning technology aims to protect financial services and e-commerce companies ... |
| 29.04.2020 | Genespire Raises €16M in Series A Financing | Genespire, a Milan, Italy-based biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, closed a €16M Series A financing. Sofinnova Partners made the investment. The compa... |
Show more